HR 2815
117th Congress
House
Health
Health care costs and insurance
Medicare
Prescription drugs
Product development and innovation
BIOSIM Act
Everywhere this bill has been
5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 23, 2021
Referred to the Subcommittee on Health.
Apr 22, 2021
Referred to the Subcommittee on Social Security.
Apr 22, 2021
Referred to the Subcommittee on Health.
Apr 22, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 22, 2021
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act
This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.
What's happening now
Referred to the Subcommittee on Health.
Related & companion bills
2
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
5
Cosponsors
3
Cite this page
U.S. Congress. (2026). H.R. 2815: BIOSIM Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-2815/
"H.R. 2815: BIOSIM Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-2815/.
H.R. 2815, 117th Cong. (2026), https://openamerica.io/bill/117-HR-2815/.
[H.R. 2815: BIOSIM Act](https://openamerica.io/bill/117-HR-2815/)